Electra Therapeutics, Inc. ETRA
NASDAQ
Recommendation
Dividend Power Score
Prev Close
Volume
--
Avg Vol (90D)
--
Market Cap
Dividend & Yield
--
P/E (TTM)
--
EPS (TTM)
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Net Income | -92.86% | -92.86% | |||
| Total Depreciation and Amortization | -- | -- | |||
| Total Amortization of Deferred Charges | -- | -- | |||
| Total Other Non-Cash Items | 90.58% | 90.58% | |||
| Change in Net Operating Assets | 1,452.95% | 1,452.95% | |||
| Cash from Operations | -57.48% | -57.48% | |||
| Capital Expenditure | 76.72% | 76.72% | |||
| Sale of Property, Plant, and Equipment | -- | -- | |||
| Cash Acquisitions | -- | -- | |||
| Divestitures | -- | -- | |||
| Other Investing Activities | 2,186.66% | 2,186.66% | |||
| Cash from Investing | 2,484.68% | 2,484.68% | |||
| Total Debt Issued | -- | -- | |||
| Total Debt Repaid | -- | -- | |||
| Issuance of Common Stock | -- | -- | |||
| Repurchase of Common Stock | -- | -- | |||
| Issuance of Preferred Stock | -- | -- | |||
| Repurchase of Preferred Stock | -- | -- | |||
| Total Dividends Paid | -- | -- | |||
| Other Financing Activities | -- | -- | |||
| Cash from Financing | 24.02% | 24.02% | |||
| Foreign Exchange rate Adjustments | -- | -- | |||
| Miscellaneous Cash Flow Adjustments | -- | -- | |||
| Net Change in Cash | 106.87% | 106.87% | |||